The 1 analysts offering 12-month price forecasts for Enlivex Therapeutics Ltd have a median target of 12.00, with a high estimate of 12.00 and a low estimate of 12.00. The median estimate represents a +679.22% increase from the last price of 1.54.
The current consensus among 1 polled investment analysts is to Buy stock in Enlivex Therapeutics Ltd. This rating has held steady since July, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.41
Reporting Date Nov 20
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.